Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2005
Business Overview: The Company manufactures and sells scientific instruments and devices for research and development. During the quarter, the Company realigned its reporting into two segments: Apparatus and Instrumentation (approx. 73% of revenue) and Capital Equipment (approx. 27% of revenue). In July 2005, subsequent to the reporting period, the Company announced plans to divest the Capital Equipment Business Segment due to underperformance.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2005 |
Six Months Ended June 30, 2005 |
Six Months Ended June 30, 2004 |
|---|---|---|---|
| Total Revenues | $21,724 | $44,159 | $44,625 |
| Net Income (Loss) | $(27,379) | $(27,177) | $247 |
| Operating Income (Loss) | $(23,177) | $(22,671) | $770 |
| Cash and Cash Equivalents | $13,245 | $13,245 | $10,515 |
| Long-Term Debt | $15,227 | $15,227 | $16,540 |
| Net Cash Provided by Operating Activities | N/A | $1,800 | $5,005 |
Note: Long-term debt includes current installments ($27k) and long-term portion ($15,200k) as of June 30, 2005.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 3.3% for the quarter and 1.0% for the six months compared to the prior year. The Capital Equipment segment drove this decline, with revenues down 20.3% (quarter) and 15.0% (six months). The Apparatus and Instrumentation segment saw modest growth of 4.2% and 5.2%, respectively.
- Significant Impairments: The Company recorded $17.9 million in asset abandonments and impairments during the quarter. This included approximately $8.0 million for long-lived assets and $9.9 million for goodwill within the Capital Equipment segment due to decreased revenues and margins.
- Restructuring Charges: Restructuring expenses totaled $0.97 million for the quarter and $0.97 million for the six months (compared to $0.16 million and $0.42 million in the prior year periods). These charges included a $3.5 million inventory write-off for rationalized products.
- Income Tax Expense: Income tax expense increased significantly to $3.9 million for the six months ended June 30, 2005, primarily due to a $3.5 million increase in the valuation allowance for deferred tax assets, driven by the underperformance of the Capital Equipment segment.
- Segment Realignment: The Company shifted from a single-segment reporting structure to two segments (Apparatus and Instrumentation; Capital Equipment) effective Q2 2005.
Guidance, Outlook, and Risks
- Divestiture Plan: Management announced plans in July 2005 to divest the Capital Equipment Business Segment to focus resources on the Apparatus and Instrumentation segment. The Company expects revenue growth without further acquisitions to be below historic levels or to slightly decline for 2005.
- Liquidity and Capital: The Company has a $20 million credit facility with $15.2 million drawn as of June 30, 2005. Management believes current cash, operating cash flow, and debt capacity are sufficient for at least 12 months. However, the Company is currently prohibited from accessing public debt or equity markets until it provides historical audited financial statements for a previous acquisition.
- Internal Control Weaknesses: The Company identified material weaknesses in internal controls over financial reporting related to income tax accounting and the lack of effective controls over material journal entries. This resulted in a material adjustment to impairment expenses recorded in Q2 2005.
- Key Risks: Risks include the inability to complete the divestiture on favorable terms, potential disruption to the remaining business, reliance on the pharmaceutical/biotech industries, foreign currency fluctuations, and the cyclical nature of the capital equipment market.
Investor Verification Checklist
- Divestiture Status: Verify the progress and terms of the planned divestiture of the Capital Equipment segment announced in July 2005.
- Internal Controls: Review the remediation plan for the identified material weaknesses in internal controls over financial reporting.
- Capital Constraints: Confirm the timeline for resolving the SEC requirement regarding audited financial statements for previous acquisitions to regain access to public capital markets.
- Segment Performance: Monitor the standalone performance of the Apparatus and Instrumentation segment post-divestiture to validate the strategic shift.
- Debt Covenants: Assess compliance with financial covenants in the $20 million credit facility, particularly given the recent operating losses and impairment charges.